Jury Awards Damages to Bayer for Hemophilia Patent Infringement

WILMINGTON, DE – After a week-long trial and several hours of deliberation, a Delaware federal jury has found that Baxalta Inc. infringed on our client Bayer’s hemophilia treatment patent (U.S. Patent 9,364,520) which treats hemophilia and awarded our client $155 million.

Bayer AG was represented by Sidley Austin LLP and Morris, Nichols, Arsht & Tunnell LLP.  Impact Trial’s team members were Leah Tran, Alex Bievenour, Becky Lavernoich and the team was led by Thomas S.Y. Lee. Impact provided support in the conceptualization, design, production and presentation of demonstrative evidence for this matter.

We are incredibly proud to serve Bayer and its counsel.

Bayer Healthcare LLC v. Baxalta Incorporated et al. case number 1:16-cv-01122, in the U.S. District Court for the District of Delaware.